{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:39:26Z","timestamp":1793036366882,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T00:00:00Z","timestamp":1792972800000},"content-version":"vor","delay-in-days":101,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Natural Science Foundation of Chongqong city,China","award":["CSTB2025NSCQ-GPX1208"],"award-info":[{"award-number":["CSTB2025NSCQ-GPX1208"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02738-y","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T01:15:45Z","timestamp":1784250945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Remodeling of the tumor microenvironment in muscle-invasive bladder cancer: insights from single-cell and spatial transcriptomics after neoadjuvant immunochemotherapy"],"prefix":"10.1186","volume":"25","author":[{"given":"Guozhi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongtang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqing","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyu","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"1","key":"2738_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2738_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskj\u00f8t","year":"2023","unstructured":"Dyrskj\u00f8t L, Hansel DE, Efstathiou JA, et al. Bladder cancer. Nat Rev Dis Primers. 2023;9(1):58.","journal-title":"Nat Rev Dis Primers"},{"key":"2738_CR3","doi-asserted-by":"crossref","unstructured":"Lopez-Beltran A, Cookson MS, Guercio BJ, et al. Advances in diagnosis and treatment of bladder cancer. BMJ (Clinical research ed), 2024; 384(e076743).","DOI":"10.1136\/bmj-2023-076743"},{"issue":"5","key":"2738_CR4","first-page":"404","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70(5):404\u201323.","journal-title":"CA Cancer J Clin"},{"key":"2738_CR5","volume":"26","author":"LP Rhea","year":"2021","unstructured":"Rhea LP, Mendez-Marti S, Kim D, et al. Role of immunotherapy in bladder cancer. Cancer Treat Res Commun. 2021;26:100296.","journal-title":"Cancer Treat Res Commun"},{"issue":"4","key":"2738_CR6","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/JU.0000000000003846","volume":"211","author":"JM Holzbeierlein","year":"2024","unstructured":"Holzbeierlein JM, Bixler BR, Buckley DI, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment. J Urol. 2024;211(4):533\u20138.","journal-title":"J Urol"},{"issue":"1","key":"2738_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2023","unstructured":"Alfred Witjes J, Max Bruins H, CARRI\u00f3N A, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur Urol. 2023;85(1):17\u201331.","journal-title":"Eur Urol"},{"issue":"9","key":"2738_CR8","doi-asserted-by":"publisher","first-page":"5851","DOI":"10.1245\/s10434-024-15725-8","volume":"31","author":"M Zhang","year":"2024","unstructured":"Zhang M, Wu J, Zhang Y, et al. Recent advances of neoadjuvant immunotherapy for urothelial bladder cancer. Ann Surg Oncol. 2024;31(9):5851\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"2738_CR9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer Cell. 2020;37(4):443\u201355.","journal-title":"Cancer Cell"},{"key":"2738_CR10","doi-asserted-by":"crossref","unstructured":"Pang K, Shi Z D, Wei L Y, et al. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2023; 66(100907).","DOI":"10.1016\/j.drup.2022.100907"},{"key":"2738_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","volume":"40","author":"MD Vesely","year":"2022","unstructured":"Vesely MD, Zhang T, Chen L. Resistance mechanisms to anti-PD cancer immunotherapy. Annu Rev Immunol. 2022;40:45\u201374.","journal-title":"Annu Rev Immunol"},{"key":"2738_CR12","doi-asserted-by":"crossref","unstructured":"Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Therapeutic. 2021; 221(107753).","DOI":"10.1016\/j.pharmthera.2020.107753"},{"key":"2738_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","volume":"387","author":"T Wu","year":"2017","unstructured":"Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett. 2017;387:61\u20138.","journal-title":"Cancer Lett"},{"issue":"6","key":"2738_CR14","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s43018-025-00986-3","volume":"6","author":"K Aliazis","year":"2025","unstructured":"Aliazis K, Christofides A, Shah R, et al. The tumor microenvironment\u2019s role in the response to immune checkpoint blockade. Nat Cancer. 2025;6(6):924\u201337.","journal-title":"Nat Cancer"},{"issue":"4","key":"2738_CR15","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s12026-024-09483-8","volume":"72","author":"W Liu","year":"2024","unstructured":"Liu W, Zhou H, Lai W, et al. The immunosuppressive landscape in tumor microenvironment. Immunol Res. 2024;72(4):566\u201382.","journal-title":"Immunol Res"},{"issue":"4","key":"2738_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s12032-025-02641-4","volume":"42","author":"DD Shah","year":"2025","unstructured":"Shah DD, Chorawala MR, Raghani NR, et al. Tumor microenvironment: recent advances in understanding and its role in modulating cancer therapies. Med Oncology (Northwood, London, England). 2025;42(4):117.","journal-title":"Med Oncology (Northwood, London, England)"},{"issue":"3","key":"2738_CR17","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1097\/MJT.0000000000000934","volume":"29","author":"VM Konala","year":"2022","unstructured":"Konala VM, Adapa S, Aronow WS. Immunotherapy in bladder cancer. Am J Ther. 2022;29(3):e334\u20137.","journal-title":"Am J Ther"},{"issue":"3","key":"2738_CR18","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ccell.2023.01.010","volume":"41","author":"O Elhanani","year":"2023","unstructured":"Elhanani O, Ben-Uri R, Keren L. Spatial profiling technologies illuminate the tumor microenvironment. Cancer Cell. 2023;41(3):404\u201320.","journal-title":"Cancer Cell"},{"key":"2738_CR19","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1146\/annurev-immunol-110519-071134","volume":"39","author":"X Ren","year":"2021","unstructured":"Ren X, Zhang L, Zhang Y, et al. Insights gained from single-cell analysis of immune cells in the tumor microenvironment. Annu Rev Immunol. 2021;39:583\u2013609.","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"2738_CR20","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41577-021-00537-8","volume":"21","author":"M Reina-Campos","year":"2021","unstructured":"Reina-Campos M, Scharping NE, Goldrath AW. CD8(+) T cell metabolism in infection and cancer. Nat Rev Immunol. 2021;21(11):718\u201338.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2738_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen S, Saeed A, Liu Q, et al. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. 2023;8(1):207.","journal-title":"Signal Transduct Target Ther"},{"issue":"21","key":"2738_CR22","doi-asserted-by":"publisher","first-page":"6174","DOI":"10.1111\/febs.15726","volume":"288","author":"S Yan","year":"2021","unstructured":"Yan S, Wan G. Tumor-associated macrophages in immunotherapy. FEBS J. 2021;288(21):6174\u201386.","journal-title":"FEBS J"},{"issue":"4","key":"2738_CR23","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.ccell.2015.02.015","volume":"27","author":"B Ruffell","year":"2015","unstructured":"Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015;27(4):462\u201372.","journal-title":"Cancer Cell"},{"issue":"1","key":"2738_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/cac2.12613","volume":"45","author":"J Yao","year":"2025","unstructured":"Yao J, Ji L, Wang G, et al. Effect of neutrophils on tumor immunity and immunotherapy resistance with underlying mechanisms. Cancer Commun. 2025;45(1):15\u201342.","journal-title":"Cancer Commun"},{"issue":"6","key":"2738_CR25","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.cell.2024.02.005","volume":"187","author":"Y Wu","year":"2024","unstructured":"Wu Y, Ma J, Yang X, et al. Neutrophil profiling illuminates anti-tumor antigen-presenting potency. Cell. 2024;187(6):1422-39.e24.","journal-title":"Cell"},{"issue":"5","key":"2738_CR26","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nrc1877","volume":"6","author":"R Kalluri","year":"2006","unstructured":"Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6(5):392\u2013401.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2738_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2023.102927","volume":"55","author":"T Wang","year":"2024","unstructured":"Wang T, Ding G, Wang X, et al. Expression of EPB41L2 in cancer-associated fibroblasts: prognostic implications for bladder cancer and response to immunotherapy. Arch Med Res. 2024;55(1):102927.","journal-title":"Arch Med Res"},{"issue":"1","key":"2738_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2024.11.011","volume":"43","author":"CT Kureshi","year":"2025","unstructured":"Kureshi CT, Dougan SK. Cytokines in cancer. Cancer Cell. 2025;43(1):15\u201335.","journal-title":"Cancer Cell"},{"issue":"3","key":"2738_CR29","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s43018-023-00521-2","volume":"4","author":"DE Speiser","year":"2023","unstructured":"Speiser DE, Chijioke O, Schaeuble K, et al. CD4(+) T cells in cancer. Nat Cancer. 2023;4(3):317\u201329.","journal-title":"Nat Cancer"},{"issue":"12","key":"2738_CR30","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow A, Perica K, Klebanoff CA, et al. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19(12):775\u201390.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"2738_CR31","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, et al. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21(10):1089\u2013108.","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"2738_CR32","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.it.2024.02.005","volume":"45","author":"M Guo","year":"2024","unstructured":"Guo M, Liu MYR, Brooks DG. Regulation and impact of tumor-specific CD4(+) T cells in cancer and immunotherapy. Trends Immunol. 2024;45(4):303\u201313.","journal-title":"Trends Immunol"},{"issue":"1","key":"2738_CR33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13058-020-01267-w","volume":"22","author":"M Kim","year":"2020","unstructured":"Kim M, Chung YR, Kim HJ, et al. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast. Breast Cancer Res. 2020;22(1):32.","journal-title":"Breast Cancer Res"},{"issue":"7967","key":"2738_CR34","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41586-023-06199-x","volume":"618","author":"B Kruse","year":"2023","unstructured":"Kruse B, Buzzai AC, Shridhar N, et al. CD4(+) T cell-induced inflammatory cell death controls immune-evasive tumours. Nature. 2023;618(7967):1033\u201340.","journal-title":"Nature"},{"key":"2738_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010275","author":"Y Subbannayya","year":"2020","unstructured":"Subbannayya Y, Haug M, Pinto SM, et al. The proteomic landscape of resting and activated CD4+ T cells reveal insights into cell differentiation and function. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms22010275.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"2738_CR36","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1038\/s41590-022-01326-8","volume":"23","author":"B Zhao","year":"2022","unstructured":"Zhao B, Gong W, Ma A, et al. SUSD2 suppresses CD8(+) T cell antitumor immunity by targeting IL-2 receptor signaling. Nat Immunol. 2022;23(11):1588\u201399.","journal-title":"Nat Immunol"},{"issue":"19","key":"2738_CR37","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1016\/j.cell.2023.07.036","volume":"186","author":"J MASSAGU\u00e9","year":"2023","unstructured":"MASSAGU\u00e9 J, Sheppard D. TGF-\u03b2 signaling in health and disease. Cell. 2023;186(19):4007\u201337.","journal-title":"Cell"},{"key":"2738_CR38","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1146\/annurev-immunol-101921-045939","volume":"41","author":"W Chen","year":"2023","unstructured":"Chen W. TGF-\u03b2 regulation of T cells. Annu Rev Immunol. 2023;41:483\u2013512.","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"2738_CR39","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.trecan.2023.05.003","volume":"9","author":"MA Salkeni","year":"2023","unstructured":"Salkeni MA, Naing A. Interleukin-10 in cancer immunotherapy: from bench to bedside. Trends Cancer. 2023;9(9):716\u201325.","journal-title":"Trends Cancer"},{"issue":"6","key":"2738_CR40","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-023-02371-y","volume":"29","author":"Y Chu","year":"2023","unstructured":"Chu Y, Dai E, Li Y, et al. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat Med. 2023;29(6):1550\u201362.","journal-title":"Nat Med"},{"issue":"9","key":"2738_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107588","volume":"26","author":"H Li","year":"2023","unstructured":"Li H, Liu H, Liu Y, et al. Exploring the dynamics and influencing factors of CD4 T cell activation using single-cell RNA-seq. iScience. 2023;26(9):107588.","journal-title":"iScience"},{"issue":"8","key":"2738_CR42","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1038\/s12276-025-01516-y","volume":"57","author":"JO Choi","year":"2025","unstructured":"Choi JO, Seo Y, Hwang SS. Guardians of silence: transcriptional networks in T cell quiescence. Exp Mol Med. 2025;57(8):1663\u201372.","journal-title":"Exp Mol Med"},{"issue":"10","key":"2738_CR43","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.immuni.2023.09.005","volume":"56","author":"JR Giles","year":"2023","unstructured":"Giles JR, Globig AM, Kaech SM, et al. CD8(+) T cells in the cancer-immunity cycle. Immunity. 2023;56(10):2231\u201353.","journal-title":"Immunity"},{"issue":"11","key":"2738_CR44","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1038\/s12276-023-01105-x","volume":"55","author":"CH Koh","year":"2023","unstructured":"Koh CH, Lee S, Kwak M, et al. CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential. Exp Mol Med. 2023;55(11):2287\u201399.","journal-title":"Exp Mol Med"},{"issue":"6\u20137","key":"2738_CR45","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.molimm.2010.12.014","volume":"48","author":"K Hayashi","year":"2011","unstructured":"Hayashi K, Kamikawa Y. HSP90 is crucial for regulation of LAT expression in activated T cells. Mol Immunol. 2011;48(6\u20137):941\u20136.","journal-title":"Mol Immunol"},{"issue":"12","key":"2738_CR46","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41423-024-01232-z","volume":"21","author":"J Kzhyshkowska","year":"2024","unstructured":"Kzhyshkowska J, Shen J, Larionova I. Targeting of TAMs: can we be more clever than cancer cells? Cell Mol Immunol. 2024;21(12):1376\u2013409.","journal-title":"Cell Mol Immunol"},{"key":"2738_CR47","doi-asserted-by":"crossref","unstructured":"Yang L, Li A, Yu W, et al. Blockade of purine metabolism reverses macrophage immunosuppression and enhances anti-tumor immunity in non-small cell lung cancer. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2025; 78(101175).","DOI":"10.1016\/j.drup.2024.101175"},{"issue":"10","key":"2738_CR48","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1136\/gutjnl-2018-316324","volume":"68","author":"C Lin","year":"2019","unstructured":"Lin C, He H, Liu H, et al. Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer. Gut. 2019;68(10):1764\u201373.","journal-title":"Gut"},{"issue":"1","key":"2738_CR49","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, Xu J, Wang W, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131.","journal-title":"Mol Cancer"},{"issue":"1","key":"2738_CR50","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-023-01860-5","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang H, Yue X, Chen Z, et al. Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials. Mol Cancer. 2023;22(1):159.","journal-title":"Mol Cancer"},{"issue":"7","key":"2738_CR51","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","volume":"55","author":"D Yang","year":"2023","unstructured":"Yang D, Liu J, Qian H, et al. Cancer-associated fibroblasts: from basic science to anticancer therapy. Exp Mol Med. 2023;55(7):1322\u201332.","journal-title":"Exp Mol Med"},{"issue":"1","key":"2738_CR52","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12929-024-01099-2","volume":"32","author":"Z Cao","year":"2025","unstructured":"Cao Z, Quazi S, Arora S, et al. Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects. J Biomed Sci. 2025;32(1):7.","journal-title":"J Biomed Sci"},{"issue":"6657","key":"2738_CR53","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1126\/science.ade2292","volume":"381","author":"R Bill","year":"2023","unstructured":"Bill R, Wirapati P, Messemaker M, et al. CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers. Science (New York, NY). 2023;381(6657):515\u201324.","journal-title":"Science (New York, NY)"},{"key":"2738_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113944","volume":"147","author":"Z Huang","year":"2025","unstructured":"Huang Z, Li Y, Liu Q, et al. SPP1-mediated M2 macrophage polarization shapes the tumor microenvironment and enhances prognosis and immunotherapy guidance in nasopharyngeal carcinoma. Int Immunopharmacol. 2025;147:113944.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"2738_CR55","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1158\/0008-5472.CAN-24-4916","volume":"86","author":"S Liu","year":"2026","unstructured":"Liu S, Zhang Z, Wang Z, et al. SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts. Can Res. 2026;86(1):58\u201379.","journal-title":"Can Res"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02738-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02738-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02738-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:04:53Z","timestamp":1793034293000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02738-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2738"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02738-y","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with ethical standards and national and international guidelines. This study was approved by the Research Ethics Committee of Chongqing Medical University, and all patients provided written informed consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"252"}}